Mechanistically, BTK inhibition sensitizes CLL cells to ferroptosis by increasing the transferrin receptor (TFRC, CD71) and increasing the intracellular Fe2+ level. Here, TFRC is linked to B-cell chronic lymphocytic leukemia.